litlas
Log inCreate account

G. Bodoky

Active 1991–2025

51
Papers
31,180
Citations
44
h-index
51
i10-index

Citations

Citations per year for G. Bodoky1991: 2 citations1994: 1 citations1996: 2 citations1997: 3 citations1998: 2 citations1999: 1 citations2002: 1 citations2003: 1 citations2004: 2 citations2005: 6 citations2006: 18 citations2007: 28 citations2008: 29 citations2009: 65 citations2010: 161 citations2011: 154 citations2012: 199 citations2013: 221 citations2014: 281 citations2015: 304 citations2016: 290 citations2017: 394 citations2018: 354 citations2019: 1,360 citations2020: 1,374 citations2021: 1,222 citations2022: 786 citations2023: 625 citations2024: 860 citations2025: 394 citations2026: 9 citations1992–1993: no citations, so these years are not shown1995: no citations, so this year is not shown2000–2001: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,288 citing papers, 17.8% of this breakdownChina: 1,615 citing papers, 12.6% of this breakdownItaly: 1,031 citing papers, 8% of this breakdownJapan: 841 citing papers, 6.5% of this breakdownGermany: 791 citing papers, 6.2% of this breakdownUnited Kingdom: 660 citing papers, 5.1% of this breakdownFrance: 611 citing papers, 4.8% of this breakdownSpain: 588 citing papers, 4.6% of this breakdownSouth Korea: 384 citing papers, 3% of this breakdownNetherlands: 310 citing papers, 2.4% of this breakdownBelgium: 301 citing papers, 2.3% of this breakdownCanada: 289 citing papers, 2.3% of this breakdown
0%17.8%Other 24.4%

Institutions

Fields

  • Medicine76.9%
  • Biochemistry, Genetics and Molecular Biology16%
  • Immunology and Microbiology2.5%
  • Materials Science1.2%
  • Engineering0.7%
  • Nursing0.5%
  • Other2.2%

Topics

  • Colorectal Cancer Treatments and Studies9.6%
  • Hepatocellular Carcinoma Treatment and Prognosis7.6%
  • Gastric Cancer Management and Outcomes4.2%
  • Cancer Immunotherapy and Biomarkers3.9%
  • Pancreatic and Hepatic Oncology Research3.9%
  • Cancer Genomics and Diagnostics3.7%
  • Other67.1%

Coauthors

All papers

Open in search
  1. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Jordi Bruix, Shukui Qin, Philippe Merle, Alessandro Granito, Yi‐Hsiang Huang, G. Bodoky, Marc Pracht, Osamu Yokosuka, Olivier Rosmorduc, В. В. Бредер, René Gerolami, Gianluca Masi, Paul J. Ross, Tianqiang Song, Jean-Pierre Bronowicki, Isabelle Ollivier‐Hourmand, Masatoshi Kudo, Ann‐Lii Cheng, Josep M. Llovet, Richard S. Finn, Marie-Aude LeBerre, Annette Baumhauer, Gerold Meinhardt, Guohong Han - The Lancet 2016 cited by 3,663

  2. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    Authors: Eric Van Cutsem, Andrés Cervantes, René Adam, Alberto Sobrero, J. Han van Krieken, Dan Aderka, E. Aranda Aguilar, Alberto Bardelli, Al B. Benson, G. Bodoky, Fortunato Ciardiello, André D’Hoore, Eduardo Díaz‐Rubio, Jean‐Yves Douillard, Michel Ducreux, Alfredo Falcone, Axel Grothey, Thomas Gruenberger, Karin Haustermans, Volker Heinemann, Paulo M. Hoff, C.-H. Köhne, Roberto Labianca, Pierre Laurent‐Puig, Brigette Ma, Tim Maughan, Kei Muro, Nicola Normanno, Pia Österlund, Wim J.G. Oyen, Demetris Papamichael, George Pentheroudakis, Per Pfeiffer, Timothy Price, Cornelis J.A. Punt, Jens Ricke, A. Roth, Ramón Salazar, Werner Scheithauer, Hans‐Joachim Schmoll, Josep Tabernero, Julien Taı̈eb, Sabine Tejpar, Harpreet Wasan, Takayuki Yoshino, Aziz Zaanan, Dirk Arnold - Annals of Oncology 2016 cited by 3,449

  3. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

    Authors: H. Wilke, Kei Muro, Eric Van Cutsem, Sang-Cheul Oh, G. Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Oleg Lipatov, Tae‐You Kim, David Cunningham, Philippe Rougier, Yoshito Komatsu, Jaffer A. Ajani, Michael Emig, Roberto Carlesi, David Ferry, Kumari Chandrawansa, Jonathan D. Schwartz, Atsushi Ohtsu - The Lancet Oncology 2014 cited by 2,471

  4. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

    Authors: Andrea Wang‐Gillam, Chung‐Pin Li, G. Bodoky, Andrew Dean, Yan‐Shen Shan, Gayle Jameson, Teresa Macarulla, Kyung-Hun Lee, David Cunningham, J.F. Blanc, Richard Hubner, Chang‐Fang Chiu, Gilberto Schwartsmann, Jens T. Siveke, Fadi Braiteh, Victor Moyo, Bruce Belanger, Navreet Dhindsa, Eliel Bayever, Daniel D. Von Hoff, Li‐Tzong Chen, Clarence S. Adoo, T Anderson, Jamil Asselah, Alan A. Azambuja, Carolyn Bampton, Carlos H. Barrios, Tanios Bekaii‐Saab, Bohuslav Melichar, David Chang, Jen‐Shi Chen, Yeu‐Chin Chen, Hye Jin Choi, Ik Joo Chung, Vincent Chung, Tibor Csőszi, Antonio Cubillo, Linda C. DeMarco, Maike de Wit, Tomislav Dragovich, W. Jeff Edenfield, Luis Fein, Fábio Franke, Martin Fuchs, Vega Gonzales-Cruz, Alberto Gozza, Rivera Herrero Fernando, Rosario Vincenzo Iaffaioli, Jitka Jakesova, Zsuzsanna Kahán, Misagh Karimi, Jun Suk Kim, Ernesto Korbenfeld, István Láng, Fa-Chyi Lee, Kuan‐Der Lee, Lara Lipton, Wen Wee, László Mangel, Raul Mena, Daniel H. Palmer, Shubham Pant, Joon Oh Park, Paolo Piacentini, Uwe Pelzer, Javier Gállego, Cooray Prasad, Kun‐Ming Rau, Jean‐Luc Raoul, Donald Richards, Paul J. Ross, Luís Alberto Schlittler, Martin Šmakal, V. Stahalova, Cora N. Sternberg, Thomas Seufferlein, Niall C. Tebbutt, J. Vinholes, Raymond Wadlow, Milkos Wenczl, Mark Wong - The Lancet 2015 cited by 1,200

  5. Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

    Authors: Jean‐Yves Douillard, Kelly S. Oliner, Salvatore Siena, Josep Tabernero, Ronald L. Burkes, Mario Barugel, Yves Humblet, G. Bodoky, David Cunningham, Jacek Jassem, Fernando Rivera, Ilona Kocáková, Paul Ruff, Maria Błasińska-Morawiec, Martin Šmakal, Jean Luc Canon, M. Rother, Richard T. Williams, Alan Rong, Jeffrey S. Wiezorek, Roger Sidhu, Scott D. Patterson - New England Journal of Medicine 2013 cited by 2,247

  6. Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

    Authors: Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, J. Załuski, Chung-Rong Chang Chien, Anatoly Makhson, Geert D’Haens, Tamás Pintér, Robert Lim, G. Bodoky, Jae Kyung Roh, Gunnar Folprecht, Paul Ruff, Christopher Stroh, Sabine Tejpar, Michael Schlichting, Johannes Nippgen, Philippe Rougier - New England Journal of Medicine 2009 cited by 3,868

  7. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

    Authors: Josep Tabernero, Takayuki Yoshino, Allen Lee Cohn, Radka Obermannová, G. Bodoky, Rocio García‐Carbonero, Tudor–Eliade Ciuleanu, David C. Portnoy, Eric Van Cutsem, Axel Grothey, Jana Prausová, Pilar García‐Alfonso, Kentaro Yamazaki, Philip R. Clingan, Sara Lonardi, Tae Won Kim, Lorinda Simms, Shao-Chun Chang, Federico Nasroulah - The Lancet Oncology 2015 cited by 955

  8. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study

    Authors: Peter Thuss‐Patience, Manish A. Shah, Atsushi Ohtsu, Eric Van Cutsem, Jaffer A. Ajani, Hugo R. Castro, Wasat Mansoor, Hyun Cheol Chung, G. Bodoky, Kohei Shitara, Gail D. Lewis Phillips, T. van der Horst, Marie-Laurence Harle-Yge, Betsy Althaus, Yoon‐Koo Kang - The Lancet Oncology 2017 cited by 541

  9. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer

    Authors: J.-Y. Douillard, Salvatore Siena, J Cassidy, Josep Tabernero, Ronald L. Burkes, Mario Barugel, Yves Humblet, G. Bodoky, David Cunningham, Jacek Jassem, Fernando Rivera, Ilona Kocáková, Paul Ruff, Maria Błasińska-Morawiec, Martin Šmakal, J.-L. Canon, M. Rother, Kelly S. Oliner, Ying Tian, Feng Xu, R. Sidhu - Annals of Oncology 2014 cited by 604

  10. Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

    Authors: Margaret A. Tempero, Uwe Pelzer, Eileen M. O’Reilly, Jordan M. Winter, Do‐Youn Oh, Chung‐Pin Li, Giampaolo Tortora, Heung-Moon Chang, Charles D. Lopez, Tanios Bekaii‐Saab, Andrew H. Ko, Armando Santoro, Joon Oh Park, Marcus Smith Noel, Giovanni Luca Frassineti, Yan‐Shen Shan, Andrew Dean, Hanno Riess, Eric Van Cutsem, Jordan Berlin, Philip Philip, Malcolm J. Moore, David Goldstein, Josep Tabernero, Mingyu Li, Stefano Ferrara, Yvan Le Bruchec, George Zhang, Brian Lu, Andrew V. Biankin, Michele Reni, Richard A. Epstein, Paul L. Vasey, Jeremy Shapiro, Matthew Burge, Yu Jo Chua, Marion Harris, Nick Pavlakis, Niall C. Tebbutt, Gerald W. Prager, Christian Dittrich, Friedrich Längle, Kathrin Philipp‐Abbrederis, Richard Greil, Herbert Stöger, Michael Girschikofsky, Thomas Kuehr, Jean–Luc Van Laethem, Stéphanie Laurent, Neesha C. Dhani, Yoo Joung Ko, Scot Dowden, Petr Kavan, Mustapha Édouard Tehfe, Eugen Kubala, Milan Kohoutek, Per Pfeiffer, Mette Yilmaz, Vibeke K. Parner, Tapio Salminen, Leena‐Maija Soveri, Eija Korkeila, Pia Österlund, Julien Taı̈eb, David Tougeron, Pascal Artru, François‐Xavier Caroli‐Bosc, Rosine Guimbaud, Antony Turpin, Thomas Walter, Jean‐Baptiste Bachet, Volker Kunzmann, Florian Kreth, Andreas De Block, Marino Venerito, Helmut Oettle, Meinolf Karthaus, Jörg Trojan, Gunnar Folprecht, Markus M. Lerch, Frank Kullmann, Marcel Reiser, Volker Heinemann, Marcus‐Alexander Wörns, H. Schulz, Benjamin Garlipp, Thomas Yau, Lam Stephen Chan, Balázs Juhász, László Landherr, Tamás Pintér, G. Bodoky, Zsuzsanna Kahán, Raymond McDermott, Derek G. Power, Luca Gianni, Salvatore Siena, Michèle Milella, Alfredo Falcone, Rossana Berardi and 87 more - Journal of Clinical Oncology 2022 cited by 132

  11. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

    Authors: Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo, Sara Lonardi, Salah‐Eddin Al‐Batran, Eric Van Cutsem, David H. Ilson, María Alsina, Ian Chau, Jill Lacy, Michel Ducreux, Guillermo Ariel Mendez, Alejandro Molina Alavez, Daisuke Takahari, Wasat Mansoor, Peter C. Enzinger, Vera Gorbounova, Zev A. Wainberg, Susanna Hegewisch‐Becker, David Ferry, Ji Lin, Roberto Carlesi, Mayukh Das, Manish A. Shah, Alexander Luft, Nina Karaseva, Rubén Dario Kowalyszyn, Carlos Alberto Hernández, Tibor Csőszi, Ferdinando De Vita, Per Pfeiffer, Naotoshi Sugimoto, Judit Kocsis, Andràs Csilla, G. Bodoky, Georgina Garnica Jaliffe, Светлана Проценко, Ayman Madi, Elżbieta Wójcik, Baruch Brenner, Gunnar Folprecht, Tomasz Sarosiek, Katriina Peltola, Peter Bono, Hubert Ayala, Giuseppe Aprile, Cardellino Giovanni Gerardo, Fidel David Huitzil Melendez, Alfredo Falcone, Francesco Di Costanzo, Moustapha Tehfe, Laurent Mineur, Pilar Alfonso, Radka Obermannová, Hélène Senellart, Russell Petty, Leslie Samuel, Péter Ács, Maen Hussein, M. Nechaeva, Frans Erdkamp, Elizabeth Won, Johanna C. Bendell, Javier Gállego, Sylvie Lorenzen, Bohuslav Melichar, Miguel Angel Escudero, Denis Pezet, Jean–Marc Phelip, Diego Kaen, James A. Reeves, Federico Longo Muñoz, Srinivasan Madhusudan, Carlo Barone, Luis Fein, Ángel Gómez Villanueva, Mohamed Hebbar, Jana Prausová, L. Visa Turmo, J. Vidal Barrull, Mette Yilmaz, Alex Beny, Hanneke W.M. van Laarhoven, Brian DiCarlo, Taito Esaki, Kazumasa Fujitani, Karen Geboes, Ravit Geva, Shigenori Kadowaki, Stephen Leong, Nozomu Machida, Moses S. Raj, Francisco Javier Ramírez Godinez, Ágnes Ruzsa, Hugo Ford, William Lawler, Nicolas Robert Maisey, Jiřı́ Petera, Einat Shacham‐Shmueli, Isabelle Sinapi and 44 more - The Lancet Oncology 2019 cited by 284

  12. Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

    Authors: Jean‐Yves Douillard, Salvatore Siena, James T. Cassidy, Josep Tabernero, Ronald L. Burkes, Mario Barugel, Yves Humblet, G. Bodoky, David Cunningham, Jacek Jassem, Fernando Rivera, Ilona Kocáková, Paul Ruff, Maria Błasińska-Morawiec, Martin Šmakal, Jean‐Luc Canon, M. Rother, Kelly S. Oliner, Michael Wolf, Jennifer Gansert - Journal of Clinical Oncology 2010 cited by 1,801

  13. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

    Authors: Hans‐Joachim Schmoll, Eric Van Cutsem, Alexander Stein, Vincenzo Valentini, Bengt Glimelius, Karin Haustermans, Bernard Nordlinger, Cornelis JH van de Velde, Judith Balmañà, Jarosław Reguła, Irıs D. Nagtegaal, Geerard L. Beets, Dirk Arnold, Fortunato Ciardiello, Paulo M. Hoff, David J. Kerr, C.-H. Köhne, Roberto Labianca, Timothy Price, Werner Scheithauer, Alberto Sobrero, Josep Tabernero, Dan Aderka, Sérgio Barroso, G. Bodoky, Jean‐Yves Douillard, Hesham El Ghazaly, J. Gallardo, A. Garin, Rob Glynne‐Jones, Karin Jordan, Andrey Meshcheryakov, Demetris Papamichail, Per Pfeiffer, Ioannis Souglakos, Serdar Turhal, Andrés Cervantes - Annals of Oncology 2012 cited by 1,534

  14. Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer

    Authors: Nicholas J. Vogelzang, Tomasz M. Beer, Winald R. Gerritsen, Stéphane Oudard, Paweł Wiechno, Bożena Kukiełka-Budny, Vladimír Šámal, Jaroslav Hájek, Susan Feyerabend, Vincent Khoo, Arnulf Stenzl, Tibor Csőszi, Zoran Filipovic, Frederico Gonçalves, А А Прохоров, Eric Cheung, Arif Hussain, Nuno Sousa, Amit Bahl, Syed A. Hussain, Harald Fricke, Pavla Kadlecová, Tomáš Scheiner, Roman Korolkiewicz, Jiřina Bartůňková, Radek Špíšek, VIABLE Investigators, Walter M. Stadler, Arthur Berg, Karl‐Heinz Kurth, Celestia S. Higano, Matti Aapro, Michael Krainer, Stephan Hruby, Johannes Meran, S. Polyakov, Jean‐Pascal Machiels, Thierry Roumeguère, Koen Ackaert, Nicolaas Lumen, Thierry Gil, Velko Minchev, Antoaneta Tomova, Borislav D. Dimitrov, Marchela Koleva, Antonio Juretić, Ana Fröbe, Željko Vojnović, Martin Drabek, L. Jarolím, Tomáš Büchler, Eva Kindlová, Jan Schraml, Milada Zemanová, Prausova Jana, Bohuslav Melichar, Martina Chodacká, Jan Jansa, Gedske Daugaard, Nicolas Delonchamps, Brigitte Duclos, Stéphane Culine, G. Deplanque, Sylvestre Le Moulec, Peter Hammerer, Gerald Rodemer, Manuel Ritter, Axel S. Merseburger, Marc‐Oliver Grimm, Ilija Damjanoski, Manfred Wirth, Martin Burmester, Kurt Miller, Jan Herden, Bastian Keck, Christian Wuelfing, Alexander Winter, Martin Boegemann, Ingo Kausch von Schmeling, Paolo Fornara, E. Jaeger, G. Bodoky, Zsuzsanna Pápai, Géza Böszörményi-Nagy, Paola Vanella, Héctor Soto Parrà, Rodolfo Passalacqua, Francesco Ferraù, Michele Maio, Lucia Fratino, Enrico Cortesi, Gunta Purkalne, Jolita Asadauskienė, Rasa Jančiauskienė, Skaistė Tulytė, Alvydas Česas, Marco B. Polée, Brigitte C.M. Haberkorn, Fons van de Eertwegh, Pieter van den Berg and 83 more - JAMA Oncology 2022 cited by 90

  15. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

    Authors: Florian Lordick, Yoon‐Koo Kang, Hyun Cheol Chung, Pamela Salman, Sang Cheul Oh, G. Bodoky, G. Kurteva, Constantin Volovăț, Vladimir Moiseyenko, В. А. Горбунова, Joon Oh Park, Akira Sawaki, Ilhan Celik, Heiko Götte, Helena Melezínková, Markus Moehler - The Lancet Oncology 2013 cited by 838

  16. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial

    Authors: Richard S. Finn, Philippe Merle, Alessandro Granito, Yi‐Hsiang Huang, G. Bodoky, Marc Pracht, Osamu Yokosuka, Olivier Rosmorduc, René Gerolami, Chiara Caparello, Roniel Cabrera, Charissa Chang, Weijing Sun, Marie-Aude LeBerre, Annette Baumhauer, Gerold Meinhardt, Jordi Bruix - Journal of Hepatology 2018 cited by 353

  17. Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial

    Authors: Arnaud Roth, Sabine Tejpar, Mauro Delorenzi, Pu Yan, Roberto Fiocca, Dirk Klingbiel, Daniel Dietrich, Bart Biesmans, G. Bodoky, Carlo Barone, Enrique Aranda, Bernard Nordlinger, Laura A. Cisar, Roberto Labianca, David Cunningham, Eric Van Cutsem, Fred T. Bosman - Journal of Clinical Oncology 2009 cited by 1,156

  18. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

    Authors: Aimery de Gramont, Eric Van Cutsem, Hans‐Joachim Schmoll, Josep Tabernero, Stephen Clarke, Malcolm J. Moore, David Cunningham, Thomas H. Cartwright, J. Randolph Hecht, Fernando Rivera, Seock‐Ah Im, G. Bodoky, Ramón Salazar, Frédérique Maindrault-Goebel, Einat Shacham‐Shmueli, Emilio Bajetta, Martina Makrutzki, Aijing Shang, Thierry André, Paulo M. Hoff - The Lancet Oncology 2012 cited by 526

  19. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

    Authors: G. Bodoky, Constanta Timcheva, David R. Spigel, Phillip J. Stella, Tudor–Eliade Ciuleanu, G. Pover, Niall C. Tebbutt - Investigational New Drugs 2011 cited by 230

  20. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial

    Authors: Charles S. Fuchs, Sérgio Jobim Azevedo, Takuji Okusaka, Jean‐Luc Van Laethem, Lara Lipton, Hanno Riess, Cezary Szczylik, Malcolm J. Moore, Marc Peeters, G. Bodoky, Masafumi Ikeda, Bohuslav Melichar, Radim Němeček, S. Ohkawa, Anna Świeboda-Sadlej, Sergei Tjulandin, Eric Van Cutsem, Robert D. Loberg, Vincent Haddad, Jennifer Gansert, Bruce Allen Bach, Alfredo Carrato - Annals of Oncology 2015 cited by 164

  21. Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1)

    Authors: Manish A. Shah, G. Bodoky, Alexander Starodub, David Cunningham, Desmond Yip, Zev A. Wainberg, Johanna C. Bendell, Dung Thai, Joyce He, Pankaj Bhargava, Jaffer A. Ajani - Journal of Clinical Oncology 2021 cited by 70

  22. ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology

    Authors: Jann Arends, G. Bodoky, Federico Bozzetti, Kenneth C.H. Fearon, Maurizio Muscaritoli, Guntars Selga, M.A.E. de van der Schueren, Maarten von Meyenfeldt, G. Zürcher, Rainer Fietkau, E. Aulbert, Barbara Frick, Matilda Holm, Michael Kneba, H. J. Mestrom, A. Zander - Clinical Nutrition 2006 cited by 930

  23. Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3

    Authors: Eric Van Cutsem, Roberto Labianca, G. Bodoky, C. Barone, Enrique Aranda, Bernard Nordlinger, Claire Topham, Josep Tabernero, Thierry André, Alberto Sobrero, Enrico Mini, Richard Greil, Francesco Di Costanzo, Laurence Collette, Laura A. Cisar, Xiaoxi Zhang, David Khayat, Carsten Bokemeyer, Arnaud Roth, David Cunningham - Journal of Clinical Oncology 2009 cited by 468

  24. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)

    Authors: Dieter Koeberle, Jean‐François Dufour, Gyula Demeter, Q. Li, Karin Ribi, Panagiotis Samaras, Piercarlo Saletti, A. Roth, Daniel Horber, M. Buehlmann, Dorothea Wagner, Michael Montemurro, Gábor Lakatos, Jonas Feilchenfeldt, Markus Peck‐Radosavljevic, Daniel Rauch, B. Tschanz, G. Bodoky - Annals of Oncology 2016 cited by 139